Sai Life Sciences Ltd (SAILIFE) — concall transcript | 30 June 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Sai Life Sciences reported 12% YoY revenue growth to ₹553 crores in Q1 FY27, driven by strong CRO and CDMO performance, with integrated services now serving 65% of customers and 90% retention.
🔄 What Changed
12% YoY revenue growth, 26% CRO growth, 6% CDMO growth, 65% integrated service adoption, 90% customer retention, and 19 of top 25 pharma clients as customers.
🔮 What's Next
15-20% long-term revenue growth, 28-30% EBITDA margins, INR 1,300 crores capex for peptide and conjugation capacity, and greenfield peptide facility by 2028.
💡 Investor Takeaway
Sai is transitioning from low-value chemistry to high-margin integrated CDMO services, securing sticky revenue from top pharma clients and investing in future modalities for sustainable growth.

Sai Life Sciences reported 12% YoY revenue growth to ₹553 crores in Q1 FY27, driven by 26% growth in CRO and 6% in CDMO, with integrated services now contributing 65% of revenue and 90% customer retention. Management highlighted strategic expansion into peptides, ADCs, and PROTACs, targeting a 2028 greenfield facility, while targeting 15-20% long-term revenue growth and 28-30% EBITDA margins. Capex of ₹1,300 crores includes peptide and conjugation capacity, with 65% of customers using integrated services and 19 of the top 25 global pharma firms as clients.

📄 View Original Announcement (PDF)

About Sai Life Sciences Ltd (SAILIFE)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹30,970.41 Cr P/E: 85.0 ROE: 14.6% ROCE: 20.1%

View full SAILIFE stock details →

📡 Get AI alerts when SAILIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAILIFE — Free

📊 More SAILIFE filings

See all SAILIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAILIFE files new disclosures

Track SAILIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAILIFE — Free

Free account · 2 AI queries/day